bmn-673 has been researched along with Prostatic-Neoplasms* in 5 studies
5 other study(ies) available for bmn-673 and Prostatic-Neoplasms
| Article | Year |
|---|---|
Talazoparib for newly diagnosed prostate cancer associated with significant risk reduction of disease progression.
Topics: Disease Progression; Humans; Male; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms | 2023 |
Talazoparib (Talzenna) for prostate cancer.
Topics: Humans; Male; Nitriles; Phthalazines; Prostatic Neoplasms | 2023 |
Talazoparib: a new biomarker-directed therapy in advanced prostate cancer.
Topics: Biomarkers; Humans; Male; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms | 2021 |
CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.
The observation that BRCA1- and BRCA2-deficient cells are sensitive to inhibitors of poly(ADP-ribose) polymerase (PARP) has spurred the development of cancer therapies that use these inhibitors to target deficiencies in homologous recombination Topics: Animals; BRCA1 Protein; Cell Line; CRISPR-Cas Systems; DNA Damage; DNA Repair; DNA Replication; DNA Topoisomerases, Type I; Female; Gene Editing; Genes, BRCA1; Genome; HeLa Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Neoplasms; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Ribonuclease H; Ribonucleotides; Synthetic Lethal Mutations; Xenograft Model Antitumor Assays | 2018 |
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of
Approximately 20% of metastatic prostate cancers harbor mutations in genes required for DNA repair by homologous recombination repair (HRR) such as Topics: Antineoplastic Agents; BRCA2 Protein; Cell-Free Nucleic Acids; DNA Copy Number Variations; Drug Resistance, Neoplasm; Exome Sequencing; Germ-Line Mutation; Humans; Male; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms | 2017 |